-
Zenflow announces Spring System data for benign prostatic hyperplasia
28 Apr 2025 17:12 GMT
… post-placement for individuals with benign prostatic hyperplasia (BPH) in the ZEST pilot studies … invasive treatments with safety advantages and reversibility akin to medication.
These … sharing developments with the urology community as we move toward FDA …
-
Incidence of benign prostatic hyperplasia in testicular cancer survivors in the Veteran's affairs health system.
27 Apr 2025 13:58 GMT
… been postulated to influence the development of benign prostatic hyperplasia (BPH). Our study aims to … 6-month prescription of medications. Associations with BPH were analysed, stratifying the …
-
Do We Need Referral Centers for Benign Prostatic Hyperplasia that Offer More Options with Expertise? Con.
27 Apr 2025 13:58 GMT
… prevalence, centralization of care for benign prostatic hyperplasia (BPH) would lead to massive waiting … strategy than centralization of BPH treatment would be to develop referral urologists within …
-
Initial Perioperative Data from CAPTAIN Randomized Trial Demonstrate MRI-Guided TULSA Provides Statistically Significant Improvement of Post-Operative Experience Vs. Robotic Radical Prostatectomy
29 Apr 2025 11:30 GMT
… -center randomized controlled trial aimed at comparing the … medical device company that develops and markets customizable, … cancer and benign prostatic hyperplasia (“BPH”); to men with BPH only; and … -invasive treatment of uterine fibroids and has FDA approval …
-
New Data Highlighting Effectiveness of Butterfly Medical’s Minimally Invasive Device for Benign Prostatic Hyperplasia (BPH) Treatment to Be Presented at AUA 2025
25 Apr 2025 23:47 GMT
… has developed a minimally invasive implantable device to treat BPH symptoms … :
Oral Presentation: Butterfly Pivotal Trial: A prospective, blinded, multicenter … Minimally Invasive Device for Benign Prostatic Hyperplasia (BPH) Treatment to Be Presented at …
-
Medicus Pharma Ltd. Announces a Binding Letter of Intent to Acquire Antev Ltd. for ~US$75 Million in a Share Exchange Transaction
28 Apr 2025 11:52 GMT
… (BPH). Antev has a US Food and Drug Administration (FDA) … therapy labeled specifically for treating prostate cancer in patients … email protected]
About Medicus Pharma Ltd.:
Medicus Pharma Ltd. (NASDAQ: … plans to develop Teverelix as a treatment for advanced …
-
Three-Year Data of Zenflow’s Spring System Demonstrate Durability of Clinical Benefits for Patients Suffering from BPH
26 Apr 2025 21:36 GMT
… treatment, First-Line Interventional Therapy or “FIT”, for patients suffering from benign prostatic hyperplasia (BPH … to reverse treatment if desired, more like a medication. The research … sharing developments with the urology community as we move toward FDA …
-
Boston Scientific Highlights New Clinical Insights in BPH, ED, and SUI at AUA 2025
25 Apr 2025 23:47 GMT
… Artificial Sphincter Clinical Outcomes (AUSCO) Trial (Abstract # PD02-07) … Trends in Surgical Management of Benign Prostatic Hyperplasia (BPH) Across Age Groups: Analysis …
o Implantable Penile Prosthesis Treatment for Erectile Dysfunction is Associated …
-
FDA Issues Warning on Hair-Loss Product Finasteride, Citing Side Effects
25 Apr 2025 21:43 GMT
… is used to treat hair loss and benign prostatic hyperplasia.
However, the … a developing male fetus.
Compounded drugs are not FDA-approved, … another popular hair loss treatment, minoxidil, due to … expanded access to compounded medications, Oro told Healthline …
-
Early Prostate Cancer Diagnosis Soon Possible with Simple Urine Sample
29 Apr 2025 20:01 GMT
… rather harmless conditions like benign prostatic hyperplasia (BPH) or infections.
Screening … help identify new drug targets, with the … to personalize overall cancer treatments.
If these urine … from medical breakthroughs and pharmacological discoveries to the …
About
© 1995-2025